학술논문

Human Mesenchymal Stem Cell Microvesicles for Treatment of Escherichia coli Endotoxin‐Induced Acute Lung Injury in Mice
Document Type
article
Source
Stem Cells. 32(1)
Subject
Medical Biotechnology
Biomedical and Clinical Sciences
Lung
Stem Cell Research - Nonembryonic - Human
Rare Diseases
Acute Respiratory Distress Syndrome
Regenerative Medicine
Biotechnology
Stem Cell Research
Aetiology
2.1 Biological and endogenous factors
Respiratory
Acute Lung Injury
Animals
Cell-Derived Microparticles
Endotoxins
Escherichia coli
Humans
Lipopolysaccharides
Male
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
Mice
Mice
Inbred C57BL
Microscopy
Electron
Acute lung injury
Keratinocyte growth factor
Lipopolysaccharide
Mesenchymal stem cell
Microvesicles
Biological Sciences
Technology
Medical and Health Sciences
Immunology
Biological sciences
Biomedical and clinical sciences
Language
Abstract
We previously found that human mesenchymal stem cells (MSC) or its conditioned medium restored lung protein permeability and reduced alveolar inflammation following Escherichia coli endotoxin-induced acute lung injury (ALI) in an ex vivo perfused human lung in part through the secretion of soluble factors such as keratinocyte growth factor (KGF). Recently, MSC were found to release microvesicles (MVs) that were biologically active because of the presence of mRNA or miRNA with reparative properties. MVs are circular fragments of membrane released from the endosomal compartment as exosomes or shed from the surface membranes. These studies were designed to determine if MVs released by human bone marrow derived MSCs would be effective in restoring lung protein permeability and reducing inflammation in E. coli endotoxin-induced ALI in C57BL/6 mice. The intratracheal instillation of MVs improved several indices of ALI at 48 hours. Compared to endotoxin-injured mice, MVs reduced extravascular lung water by 43% and reduced total protein levels in the bronchoalveolar lavage (BAL) fluid by 35%, demonstrating a reduction in pulmonary edema and lung protein permeability. MVs also reduced the influx of neutrophils and macrophage inflammatory protein-2 levels in the BAL fluid by 73% and 49%, respectively, demonstrating a reduction in inflammation. KGF siRNA-pretreatment of MSC partially eliminated the therapeutic effects of MVs released by MSCs, suggesting that KGF protein expression was important for the underlying mechanism. In summary, human MSC-derived MVs were therapeutically effective following E. coli endotoxin-induced ALI in mice in part through the expression of KGF mRNA in the injured alveolus.